RT Journal Article
SR Electronic
T1 Characteristics, outcome and predictors of in-hospital mortality in an elderly population from a SARS-CoV-2 outbreak in a long-term care facility
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.30.20143701
DO 10.1101/2020.06.30.20143701
A1 Enrico Maria Trecarichi
A1 Maria Mazzitelli
A1 Francesca Serapide
A1 Maria Chiara Pelle
A1 Bruno Tassone
A1 Eugenio Arrighi
A1 Graziella Perri
A1 Paolo Fusco
A1 Vincenzo Scaglione
A1 Chiara Davoli
A1 Rosaria Lionello
A1 Valentina La Gamba
A1 Giuseppina Marrazzo
A1 Maria Teresa Busceti
A1 Amerigo Giudice
A1 Marco Ricchio
A1 Anna Cancelliere
A1 Elena Lio
A1 Giada Procopio
A1 Francesco Saverio Costanzo
A1 Daniela Patrizia Foti
A1 Giovanni Matera
A1 Carlo Torti
A1 IDTM UMG COVID-19 Group
YR 2020
UL http://medrxiv.org/content/early/2020/07/02/2020.06.30.20143701.abstract
AB Since December 2019, coronavirus disease 2019 (COVID-19) pandemic has spread from China all over the world, many COVID-19 outbreaks have been reported in long-term care facilities (LCTF). However, data on clinical characteristics and prognostic factors in such settings are scarce. We conducted a retrospective, observational cohort study to assess clinical characteristics and baseline predictors of mortality of COVID-19 patients hospitalized after an outbreak of SARS-CoV-2 infection in a LTCF.A total of 50 patients were included. Mean age was 80 years (SD, 12 years), and 24/50 (57.1%) patients were males. A total of 42/50 (84%) patients experienced symptoms of SARS-CoV-2 infection. The overall in-hospital mortality rate was 32%. In Cox regression, significant predictors of in-hospital mortality were: hypernatremia (HR 9.12), lymphocyte count <1000 cells/µL (HR 7.45), cardiovascular diseases other than hypertension (HR 6.41), and higher levels of serum interleukin-6 (IL-6, pg/mL) (HR 1.005).Our study shows a high in-hospital mortality rate in a cohort of elderly patients with COVID-19 and hypernatremia, lymphopenia, CVD other than hypertension, and higher IL-6 serum levels were identified as independent predictors of in-hospital mortality. Further studies are necessary to better understand and confirm our findings in the setting of a LTCF outbreak of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementnoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was notified to the Ethics Committee of the Calabria Region on May 13th, 2020 and conducted in in accordance with the declaration of Helsinki. The study was carried out using retrospectively collected and anonymized data. In Italy, such studies do not require ethical approval by an Ethics Committee as determined by the Italian Drug Agency note 20 March 2008 (GU Serie Generale n. 76 31/3/2008). The need for written informed consent was waived for patients owing to the retrospective nature of the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData cannot be made publicly available due to ethical restrictions imposed by Italian legislation and our Ethics Committee